- Home
- RC vs ORKA Comparison
RC vs ORKA Comparison
Compare RC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RC | ORKA |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.8M | 1.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RC | ORKA |
|---|---|---|
| Price | $2.17 | $28.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $5.75 | ★ $45.22 |
| AVG Volume (30 Days) | ★ 3.6M | 429.4K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 22.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.13 | $5.49 |
| 52 Week High | $7.64 | $32.28 |
Technical Indicators
Market Signals| Indicator | RC | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 28.09 | 47.41 |
| Support Level | $2.13 | $29.38 |
| Resistance Level | $2.53 | $31.35 |
| Average True Range (ATR) | 0.13 | 1.76 |
| MACD | -0.01 | -0.34 |
| Stochastic Oscillator | 5.97 | 31.82 |
Price Performance
Historical ComparisonAbout RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.